There's no rate to imply here.

The data isn't there yet — here's what's missing:

  • Caution:
    What is missing
    Humana's free cash flow fell to about $0.4B in 2025, roughly 85% below its own five-year norm, as Medicare Advantage reimbursement rates were cut, medical costs ran ahead of premiums and the company lost members and star-rating bonuses. Our fair value normalizes a one-off bad year back to typical cash flow, but this looks like a reset to a lower level of profitability rather than a single bad year — and normalizing against a median that still contains the higher-margin years would overstate what the business now earns. The read returns once a full year has been filed at the repriced margins and a five-year base can be drawn from them.

TickerMath is an educational tool, not investment advice — it computes one model from SEC filings and can be wrong. How we compute this →